NextCure, Inc. Files 8-K Report
Ticker: NXTC · Form: 8-K · Filed: Dec 10, 2024 · CIK: 1661059
| Field | Detail |
|---|---|
| Company | Nextcure, Inc. (NXTC) |
| Form Type | 8-K |
| Filed Date | Dec 10, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k
TL;DR
NextCure filed an 8-K. Check for updates.
AI Summary
On December 10, 2024, NextCure, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates or disclosures related to the company's financial status and significant occurrences. No specific financial figures or new events were detailed in the provided excerpt.
Why It Matters
This filing provides an official update from NextCure, Inc. to the SEC, which could contain material information for investors regarding the company's operations or financial health.
Risk Assessment
Risk Level: low — The provided text is a standard SEC filing notification and does not contain specific financial or operational details that would indicate immediate risk.
Key Players & Entities
- NextCure, Inc. (company) — Registrant
- December 10, 2024 (date) — Date of earliest event reported
- Beltsville, Maryland (location) — Principal executive offices location
FAQ
What is the primary purpose of this 8-K filing for NextCure, Inc.?
The filing is a Current Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, reporting "Other Events" and "Financial Statements and Exhibits" as of December 10, 2024.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is December 10, 2024.
Where are NextCure, Inc.'s principal executive offices located?
NextCure, Inc.'s principal executive offices are located at 9000 Virginia Manor Road, Suite 200, Beltsville, Maryland 20705.
What is the Commission File Number for NextCure, Inc.?
The Commission File Number for NextCure, Inc. is 001-38905.
What is the IRS Employer Identification Number for NextCure, Inc.?
The IRS Employer Identification Number for NextCure, Inc. is 47-5231247.
Filing Stats: 460 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2024-12-10 08:10:47
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share NXTC Nasdaq Glo
Filing Documents
- nxtc-20241210x8k.htm (8-K) — 48KB
- nxtc-20241210xex99d1.htm (EX-99.1) — 14KB
- nxtc-20241210xex99d1001.jpg (GRAPHIC) — 6KB
- 0001558370-24-016108.txt ( ) — 205KB
- nxtc-20241210.xsd (EX-101.SCH) — 4KB
- nxtc-20241210_def.xml (EX-101.DEF) — 3KB
- nxtc-20241210_lab.xml (EX-101.LAB) — 17KB
- nxtc-20241210_pre.xml (EX-101.PRE) — 12KB
- nxtc-20241210x8k_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events On December 10, 2024, NextCure, Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration accepted an Investigational New Drug application for initiation of a Phase 1 clinical trial to evaluate LNCB74, a B7-H4-targeting antibody-drug conjugate as a therapeutic for treating multiple cancers. A copy of this press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits. Exhibit No. Description 99.1 Press Release dated December 10, 2024 104 Cover Page Interactive Data File (embedded within the inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. November Dated: December 10, 2024 NEXTCURE, INC. By: /s/ Steven P. Cobourn Name: Steven P. Cobourn Title: Chief Financial Officer